Please login to the form below

Not currently logged in
Email:
Password:

prostate cancer

This page shows the latest prostate cancer news and features for those working in and with pharma, biotech and healthcare.

Sanofi pays $160m upfront to acquire Tidal Therapeutics

Sanofi pays $160m upfront to acquire Tidal Therapeutics

with Merck &Co’s Keytruda (pembrolizumab) in patients with high-risk melanoma and other cancer types. ... BioNTech also has a number of mRNA-based candidates in development for the treatment of a number of cancer types, including advanced melanoma,

Latest news

More from news
Approximately 65 fully matching, plus 300 partially matching documents found.

Latest Intelligence

  • Unlocking the potential of precision medicine in oncology Unlocking the potential of precision medicine in oncology

    continuum of targeted therapies now available to prostate cancer patients, including PARP inhibitors. ... Similarly, DRD testing in late stage prostate cancer is needed to identify patients who could potentially benefit from PARP inhibition.

  • Why digital is the solution to the healthcare crisis Why digital is the solution to the healthcare crisis

    Be it treatment for cancer, aches and pains, unusual lumps, headaches – the general malay that you would visit your doctor or hospital for consultation and treatment. ... Nudge behaviour, such as timely reminders for breast or prostate cancer screening,

  • The human connection: how to achieve emotive creativity in pharma The human connection: how to achieve emotive creativity in pharma

    your patients a disservice while you’re at it). We’ve been acutely aware of this balancing act in our own work; a recent film we worked on for prostate cancer ... With this as our starting point, we introduced messaging about the importance of

  • BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

    the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... In European patients, the average five-year relative survival rate was 83% for melanoma, 83% for prostate cancer, 82% for breast cancer and 57% for colon

More from intelligence
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    urologists who are uniquely positioned to deliver long-term care to men with prostate cancer. ... stage prostate cancer, with the hope of curing more men of the disease.”.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • MDxHealth creates new global commercial team MDxHealth creates new global commercial team

    MDxHealth has created a new global commercial team to drive the launch of SelectMDx, its new prostate cancer test. ... the commercialisation of a molecular diagnostic test for prostate cancer across Europe.”.

  • Dr Hamina Patel moves from J&J to Evgen Pharma Dr Hamina Patel moves from J&J to Evgen Pharma

    She joins the firm from Johnson and Johnson, where she was director of drug development, oncology, where she helped to build a broad portfolio of indications for its cancer drug Velcade. ... interest in prostate cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 6 fully matching, plus 18 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....

Infographics